Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Theratechnologies is a triple from here, says Leede Jones Ga
View:
Post by LouisW on Jun 07, 2023 12:42am

Theratechnologies is a triple from here, says Leede Jones Ga

https://www.cantechletter.com/2023/06/theratechnologies-is-a-triple-from-here-says-leede-jones-gable/#
Comment by palinc2000 on Jun 07, 2023 8:57am
65.2million$ R&D????? If this is a true representation of his report then this is garbage!!!
Comment by Wino115 on Jun 07, 2023 10:29am
I may be wrong since I haven't actually seen his report, but he may be referring to the accumulated historical RD spend on it, so something in the $30mil a year level over last 2 years. That may not be too far off. In general though, his reports are far better on the science than on the financials.
Comment by palinc2000 on Jun 07, 2023 12:50pm
I see what he did...He added to FY together whereas the report was written in a way to be interpreted as one financial year The bigger picture is that RD expenses  if any should be aligned with revenues and or share dilution but should NEVER NEVER NEVER NEVER be funded by loans as was done 5 yesrs ago with the Convert  I
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities